araag2/HINT huggingface dataset:
Clinical trial NCT02324010 (phase 2, status: completed)
Conditions: gastroparesis, diabetes mellitus
ICD codes: K31.84, P70.2, O24.92, Z83.3, E10.65, E10.9, E11.65, E11.9
Drugs: sitagliptin, placebo
SMILES: N[C@@H](CC(=O)N1CCN2C(C1)=NN=C2C(F)(F)F)CC1=CC(F)=C(F)C=C1F, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Type 2 diabetes (World Health Organisation (WHO) criteria), managed by diet or
             metformin alone

          -  Body mass index (BMI) 20 - 40 kg/m2

          -  Males and females (females of reproductive potential must be using an appropriate
             contraceptive method)

          -  Glycated haemoglobin (HbA1c) ≤ 8.5%

          -  Haemoglobin above the lower limit of the normal range (i.e. >135g/L for men and 115g/L
             for women), and ferritin above the lower limit of normal (i.e. >10mcg/L)

        Exclusion Criteria:

          -  Subjects with gastrointestinal disease, significant upper or lower gastrointestinal
             symptoms, or previous gastrointestinal surgery (other than uncomplicated
             appendicectomy or cholecystectomy)

          -  Other significant illness, including epilepsy, cardiovascular or respiratory disease.

          -  History of unexplained pancreatitis, chronic pancreatitis, pancreatectomy.

          -  Impaired renal or liver function (as assessed by calculated creatinine clearance < 50
             mL/min using the Cockroft-Gault equation (27) or abnormal liver function tests (> 2
             times upper limit of normal range)).

          -  Requirement for medication known to influence blood pressure and/or heart rate and/or
             gastrointestinal function, drugs with anticholinergic effects

          -  Alcohol consumption > 20 g per day

          -  Smoking > 10 cigarettes per day

          -  Pregnancy or lactation.

          -  Vegetarian

          -  Allergy to sitagliptin or any other 'gliptin'.

          -  Donation of blood within the previous 3 months

          -  Participation in any other research studies within the previous 3 months

          -  Exposure to ionising radiation for research purposes in the previous 12 months

          -  Inability to give informed consent
Clinical trial NCT02324491 (phase 2, status: terminated)
Conditions: obesity, type 2 diabetes
ICD codes: E66.8, E66.9, E66.1, O99.214, O99.215, O99.210, O99.211, E11.65, E11.9, E11.21, E11.36, E11.41, E11.42, E11.44
Drugs: zgn-440 for injectable suspension, zgn-440 placebo for injectable suspension
SMILES: CO[C@@H]1[C@@H](CC[C@]2(CO2)[C@H]1[C@@]1(C)O[C@@H]1CC=C(C)C)OC(=O)\C=C\C1=CC=C(OCCN(C)C)C=C1, CO[C@@H]1[C@@H](CC[C@]2(CO2)[C@H]1[C@@]1(C)O[C@@H]1CC=C(C)C)OC(=O)\C=C\C1=CC=C(OCCN(C)C)C=C1
Reason stopped: 
    sponsor decision to analyze available safety and efficacy data
  
Eligibility criteria:

        Inclusion Criteria:

          -  Obese with BMI ≥30 kg/m2

          -  Type 2 diabetes mellitus

          -  HbA1c of 7-11%

          -  Fasting glucose <15.5 mmol/L

          -  Treated with diet and exercise alone or with a stable regimen of metformin,
             sulfonylurea, pioglitazone, DPP-4 inhibitor, GLP-1 receptor agonist, SGLT-2 inhibitor
             or any combination of these agents

          -  Female subjects must be surgically sterile, post-menopausal or using long-acting
             contraception, which includes intrauterine devices or use of an implanted or
             injectable contraceptive

        Exclusion Criteria:

          -  Current or recent use of insulin

          -  Severe hypoglycemia within the prior 6 months

          -  Metabolic disorders or genetic disorders linked to obesity (e.g., Prader-Willi
             Syndrome)
Clinical trial NCT02324972 (phase 2, status: completed)
Conditions: atopic dermatitis
ICD codes: L20.89, L20.9
Drugs: aqx-1125, placebo
SMILES: C[C@]12CC[C@@H]([C@@H](CN)[C@@H]1CCC2=C)[C@@]1(C)CC[C@H](O)C[C@@H]1CO, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          1. Male or female aged from 18 to 65 years old

          2. Confirmed clinical diagnosis of active atopic dermatitis (AD) according to the Hanifin
             and Rajka criteria

          3. At least a 6 months history of atopic dermatitis.

          4. Body Surface Area (BSA) covered with atopic dermatitis of 1% or more

          5. Mild or moderate atopic dermatitis (IGA score of 2 or 3).

          6. TLSS of 5 or more at Day 0.

          7. Subject must use a non-medicated emollient daily for at least (≥) 7 days prior to Day
             0 and should continue using that same emollient, at the same frequency, throughout the
             study.

        Exclusion Criteria:

          1. Female subject who is pregnant or breast-feeding

          2. Unstable or clinically infected atopic dermatitis
Clinical trial NCT02325986 (phase 2, status: unknown status)
Conditions: esophageal squamous cell carcinoma
ICD codes: C22.0, C4A.9, C7B.1, C4A.0, C4A.31, C4A.51, C4A.8
Drugs: fluorouracil, cisplatin
SMILES: [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, [H][C@@]12N(C)C3=CC(OC)=C(C=C3[C@@]11CCN3CC=C[C@](CC)([C@@]13[H])[C@@]([H])(OC(C)=O)[C@]2(O)C(=O)OC)[C@]1(C[C@@]2([H])CN(CC(CC)=C2)CC2=C1NC1=CC=CC=C21)C(=O)OC
Eligibility criteria:

        Inclusion Criteria:

          1. R0 resection for primary esophageal squamous cell carcinoma with two-incision
             esophagectomy (Ivor Lewis approach)25 or three-incision (right thoracotomy, midline
             laparotomy and left cervical incisions) esophagectomy with cervical esophagogastric
             anastomosis.

          2. Absence of previous thoracic radiotherapy.

          3. Cervical and/or thoracic postoperative recurrence (biopsy proven or positron emission
             tomography/computed tomography (PET/CT) proven or follow-up computed tomography (CT)
             showed progression of disease).

          4. Absence of distant metastasis at recurrence.

          5. Eastern Cooperative Oncology Group (ECOG) performance status (PS) ≤ 2

        Exclusion Criteria:

          1. Younger than 18 or older than 70 years of age.

          2. Eastern Cooperative Oncology Group (ECOG) performance status of 3 or above

          3. Other cancer history.

          4. Serious cardiac, liver, or pulmonary disease.

          5. Previous radiotherapy history
Clinical trial NCT02326090 (phase 2, status: completed)
Conditions: dry eye syndrome
ICD codes: H04.121, H04.122, H04.123, H04.129
Drugs: cis-uca ophthalmic solution 1.0%, cis-uca ophthalmic solution 2.5%, placebo ophthalmic solution
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Key Inclusion Criteria:

          -  Be at least 18 years of age;

          -  Provide written informed consent;

          -  Have a subject reported history of dry eye;

          -  Have a history of use or desire to use eye drops.

        Key Exclusion Criteria:

          -  Have any clinically significant eye findings that require therapeutic treatment,
             and/or in the opinion of the Investigator may interfere with study parameters;

          -  Have worn contact lenses within 7 days of Visit 1 or anticipate using contact lenses
             during the study;

          -  Have previously had laser-assisted in situ keratomileusis (LASIK) surgery within the
             last 12 months;

          -  Have used Restasis® within 30 days of Visit 1;

          -  Have any planned ocular and/or lid surgeries over the study period;

          -  Be a woman who is pregnant, nursing or planning a pregnancy;

          -  Be unwilling to submit a urine pregnancy test at Visit 1 and Visit 4 (or early
             termination visit) if of childbearing potential;

          -  Have a known allergy and/or sensitivity to the study drug or its components;

          -  Have a condition or be in a situation which the Investigator feels may put the subject
             at significant risk, may confound the study results, or may interfere significantly
             with the subject's participation in the study;

          -  Be currently enrolled in an investigational drug or device study or have used an
             investigational drug or device within 30 days of Visit 1;

          -  Be unable or unwilling to follow instructions, including participation in all study
             assessments and visits.
Clinical trial NCT02328547 (phase 2, status: completed)
Conditions: irritable bowel syndrome
ICD codes: K58.2, K58.8, K58.0, K58.1, K58.9
Drugs: fecal microbiota transplantation capsules, placebo capsules
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  age 19-65 years

          -  established diagnosis of IBS-D as determined by Rome III Criteria

          -  moderate-severe disease activity (as determined by an IBS-Symptom Severity Score ≥175)

          -  persistent symptoms despite conventional therapy

          -  normal colonoscopy with biopsies in the past for work-up of IBS symptoms

          -  negative work-up for celiac disease either by duodenal biopsies or negative serologies

        Exclusion Criteria:

          -  pregnancy

          -  nursing

          -  cognitive impairment or severe neuropsychiatric comorbidities who are incapable of
             providing their own informed consent

          -  severely immunocompromised or immunosuppressed patients (e.g., organ transplant
             recipients, severe neutropenia with an absolute neutrophil count of <500cells/mL,
             current treatment or treatment within 3 months with anti-neoplastic agents and
             HIV-positive patients with CD4 counts <200cells/mm^3)

          -  treated with any antibiotics in the 3 months prior to FMT

          -  GI symptoms can be explained by the presence of an underlying organic disease
             including, underlying inflammatory bowel disease, infectious enteritis, previously
             established and untreated small intestinal bacterial overgrowth or known motility
             disorder

          -  previous FMT

          -  severe (anaphylactic) food allergy

          -  unable to comply with protocol requirements

          -  American Society of Anesthesiologists (ASA) Physical Status classification IV and V

          -  acute illness or fever on the day of planned FMT will be excluded (not randomized)
             with the option of including that subject at a future date

          -  new antidepressant started or dose of antidepressant change <3 months prior to
             enrollment

          -  elevated ESR or CRP within the past 3 months

          -  baseline laboratory abnormalities on CBC, chemistry or liver tests

          -  pain score >75 on IBS-SSS
Clinical trial NCT02333890 (phase 2, status: unknown status)
Conditions: breast cancer, invasive breast cancer
ICD codes: C79.81, D24.1, D24.2, D24.9, D49.3, C44.501, D48.60, C79.81, D24.1, D24.2, D24.9, D49.3, C44.501, D48.60
Drugs: chloroquine, placebo
SMILES: CCN(CC)CCCC(C)NC1=C2C=CC(Cl)=CC2=NC=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  newly diagnosed histologically confirmed primary invasive breast cancer who is
             currently not undergoing any treatment while awaiting surgery in the next 2-6 weeks

          -  tumour ≥ 1.5 cm by palpation or imaging

          -  ECOG performance status 0-2

          -  written informed consent for the study

        Exclusion Criteria:

          -  Known Metastatic breast cancer

          -  history of pre-existing known retinal or ocular pathology patient has only one
             functioning eye

          -  abnormal hepatic function (serum AST or ALT >3x upper limit of normal)

          -  currently on CQ or HCQ or has been on the drug within the past 3 months for other
             conditions

          -  known history of psoriasis

          -  known history of epilepsy or seizures

          -  electrocardiogram showing QT prolongation based on QTc interval >450 ms

          -  inability to comply with a study protocol (abuse of alcohol, drugs or psychotic
             states)

          -  current known pregnancy or actively nursing

          -  allergic reactions to quinolones or CQ

          -  inability to consent.
Clinical trial NCT02335294 (phase 2, status: completed)
Conditions: pain
ICD codes: N50.82, R07.2, R07.82, R10.13, R10.33, R14.1, R52
Drugs: trv130, morphine, placebo
SMILES: CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  >=18 and <=65 years of age.

          -  Plans to undergo an abdominoplasty procedure with no additional collateral procedures.

          -  Is able to understand and comply with the procedures and study requirements, and to
             provide written informed consent before any study procedure.

        Exclusion Criteria:

          -  ASA Physical Status Classification System classification of P3 or worse.

          -  Has surgical or post-surgical complications.

          -  Has clinically significant medical conditions or history of such conditions that may
             interfere with the interpretation of efficacy, safety, or tolerability data obtained
             in the trial, or may interfere with the absorption, distribution, metabolism, or
             excretion of drugs.

          -  Has previously participated in another TRV130 clinical study.
Clinical trial NCT02336425 (phase 2, status: terminated)
Conditions: asthma
ICD codes: J45.998, J82.83, J45.909, J45.991, J45.20, J45.30, J45.40
Drugs: qge031, placebo
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Reason stopped: 
    this study was terminated due to the efficacy results from an interim analysis (at the end of
    treatment epoch) of the phase ii study cqge031b2201 (nct01716754).
  
Eligibility criteria:

        Key Inclusion Criteria:

          -  A diagnosis of allergic asthma, uncontrolled on current medication.

          -  History of at least 2 asthma exacerbations during the last 1 year

          -  Forced Expiratory Volume in one second (FEV1) of ≥ 40% and ≤ 80% of the predicted
             normal value; reversibility following administration of bronchodilator.

        Key Exclusion Criteria:

          -  Use of tobacco products within the previous 6 months (Social occasional smokers may be
             included).

          -  Recent asthma attack/exacerbation or asthma worsening/ respiratory infection.
Clinical trial NCT02336815 (phase 2, status: completed)
Conditions: multiple myeloma
ICD codes: C90.01, C90.02, C90.00
Drugs: selinexor, dexamethasone
SMILES: FC(F)(F)C1=CC(=CC(=C1)C1=NN(\C=C/C(=O)NNC2=NC=CN=C2)C=N1)C(F)(F)F, C[C@@H](O[C@H]1OCCN(CC2=NNC(=O)N2)[C@H]1C1=CC=C(F)C=C1)C1=CC(=CC(=C1)C(F)(F)F)C(F)(F)F
Eligibility criteria:

        Inclusion Criteria:

        Measurable MM based on modified IMWG guidelines. Defined by at least one of the following:

          1. Serum M-protein ≥ 0.5 g/dL by serum electrophoresis (SPEP) or for IgA myeloma, by
             quantitative IgA

          2. Urinary M-protein excretion ≥ 200 mg/24 hours

          3. Free Light Chain (FLC) ≥ 100 mg/L, provided that the FLC ratio is abnormal

          4. If serum protein electrophoresis is felt to be unreliable for routine M-protein
             measurement, then quantitative Ig levels by nephelometry or turbidimetry are
             acceptable

               -  Must have previously received ≥ 3 anti-MM regimens including: an alkylating
                  agent, lenalidomide, pomalidomide, bortezomib, carfilzomib, daratumumab, and a
                  glucocorticoid. There is no upper limit on the number of prior therapies provided
                  that all other inclusion/exclusion criteria are met.

               -  MM refractory to previous treatment with one or more glucocorticoids, parenteral
                  PI (i.e., bortezomib and/or carfilzomib), IMiD (i.e., lenalidomide and/or
                  pomalidomide), and the anti-CD38 mAb, daratumumab. Refractory is defined as ≤ 25%
                  response to therapy, or progression during therapy or progression within 60 days
                  after completion of therapy.

        Exclusion Criteria:

          -  Active smoldering MM.

          -  Active plasma cell leukemia.

          -  Documented systemic amyloid light chain amyloidosis.

          -  Active CNS MM.
Clinical trial NCT02337608 (phase 2, status: completed)
Conditions: ulcerative colitis
ICD codes: K51.80, K51.813, K51.814, K51.90, K51.913, K51.914, K51.811
Drugs: glpg1205, placebo
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Male or female subjects between 18 and 75 years

          -  Documented history of UC

          -  Presence of active UC for a minimum period of 14 days prior to screening and spread
             beyond the rectum, Mayo score ≥ 6 with rectal bleeding score ≥ 1 and endoscopy score ≥
             2

          -  Absence of infectious colitis

          -  Tumor necrosis factor alpha (TNFα) inhibitor-naive subjects should have failed at
             least 1 prior conventional therapy

          -  Continuation of concurrent treatment with oral steroids (≤30 mg prednisolone eq/day),
             immunosuppressants and 5-aminosalicylates at stable dose is allowed

          -  Female subjects must have a negative blood pregnancy test, unless they are surgically
             sterile, had a hysterectomy, or have been postmenopausal for at least 1 year

          -  Subjects will have to use highly effective contraceptive methods

        Exclusion Criteria:

          -  History of sensitivity to any component of the study drug, or a history of drug or
             other allergy

          -  Any concurrent illness, condition, disability, or clinically significant abnormality
             that, in the investigator's opinion, represents a safety risk for the subject's
             participation, may affect the interpretation of data, or may prevent the subject from
             safely completing the assessments

          -  History of significant psychological, neurologic, hepatic, renal, endocrine,
             cardiovascular, GI (other than UC), pulmonary, or metabolic disease

          -  History of active infections requiring intravenous antibiotics within the past 4 weeks
             prior to screening.

          -  History of malignancy within the past 5 years; presence or history of intestinal
             malignancy

          -  History of bowel surgery within 6 months prior to screening; history of colon
             resection with < 30 cm of the colon remaining

          -  Suspicion of Crohn's disease, indeterminate colitis, microscopic colitis, ischemic
             colitis, diverticular disease-associated colitis, or radiation-induced colitis

          -  Subject who has received non-permitted UC therapies within specified timeframes,
             depending on the medication, as stated in the protocol

          -  Subject who is pregnant or lactating
Clinical trial NCT02337907 (phase 2, status: completed)
Conditions: alzheimer disease
ICD codes: G30.8, G30.9, G30.0, G30.1
Drugs: placebo, placebo, bi 409306, donepezil
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, O=S(=O)(C1=CC=CC=C1)C1=CN=C2C(C=CC=C2N2CCNCC2)=C1
Eligibility criteria:

        Inclusion criteria:

          -  Patients with early signs of dementia of Alzheimer Type

          -  Male and female patients with an age of at least 55 years

          -  Previous use of Alzheimer's Disease (AD) medications (AChEIs, memantine) is allowed up
             3 month prior to screening. Patients who are currently taking AChEIs are eligible as
             long as they have been using a stable dose for at least 3 months prior to screening
             and no change is foreseen for the duration of the study. This dose must be consistent
             with the product label in the concerned country. Patients currently taking memantine
             are excluded.

          -  Patients must have at least 6 years of formal education and fluency in the test
             language as verbally confirmed by the patient and documented by the study
             investigator.

          -  Patients must have a reliable study partner (per investigator judgement, for instance
             a family member, partner etc., guardian or, if applicable, a legal representative)

        Exclusion criteria:

          -  Cognitive impairment or dementia with any etiology other than Alzheimer's Disease (AD)

          -  Substantial concomitant cerebrovascular disease (defined by a history of a stroke /
             intracranial haemorrhagia) temporally related to the onset of worsening of cognitive
             impairment per investigator judgement

          -  Medical history or diagnosis of any of symptomatic and unstable/uncontrolled
             conditions per investigator judgement

          -  Any other psychiatric disorders such as schizophrenia, or mental retardation

          -  Previous participation in investigational drug studies of mild cognitive
             impairment/Dementia of Alzheimer Type (DAT) within three months prior to screening.
             Having received active treatment in any other study targeting disease modification of
             AD like Aß immunization and tau therapies. Previous participation in studies with
             non-prescription medications, vitamins or other nutritional formulations is allowed.

          -  Clinically significant uncompensated hearing loss in the judgment of the investigator.
             Use of hearing aids is allowed.